Participants in a clinical trial didn't like Pain Therapeutics
You see, the participants in the study were drug abusers, and Remoxy is an abuse-deterrent formulation of the same active ingredient as OxyContin. Not liking to abuse the drug is kind of the point.
Remoxy uses DURECT's
Last week, the Food and Drug Administration said that all drugmakers -- from Pfizer and Johnson & Johnson
Remoxy was originally up for review by the FDA in 2008 when the agency said it wanted more information about the abuse-deterrent part of the drug. We'll know soon enough whether Remoxy can get past the agency when the FDA makes a new decision on or around June 23. Considering the agency's new stance on prescription drug abuse and the new data that Pain and Pfizer have in hand, Remoxy should have an easier time getting liked by the FDA.
Interested in up and coming technology? Click here to get the Fool's free report, The Only Stock You Need To Profit From the NEW Technology Revolution.
Johnson & Johnson and Pfizer are Motley Fool Inside Value picks. Teva Pharmaceutical Industries is a Motley Fool Global Gains selection. Johnson & Johnson is a Motley Fool Income Investor recommendation. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Johnson & Johnson, and Teva Pharmaceutical Industries. Alpha Newsletter Account, LLC owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.